Prostate cancer (PCa) growth is mainly driven by androgen receptor (AR), and tumors that
initially respond to androgen deprivation therapy (ADT) or AR inhibition usually relapse into …

Despite recent advances in the treatment of advanced prostate cancer (PCa), metastatic
castrate-resistant PCa remains incurable at this time. The androgen receptor (AR) plays a …

Androgen deprivation therapy is an important therapy for prostate cancer (PCa) in aging
men. Under the background of castration, it is inevitable that prostate cancer will develop …

Prostate cancer at advanced stages including metastatic and castration-resistant cancer
remains incurable due to the lack of effective therapies. MiR-190a belongs to the small …

Androgen/androgen receptor (AR) signaling drives both the normal prostate development
and prostatic carcinogenesis, and patients with advanced prostate cancer often develop …

Background Cancer metastasis is well known as the most adverse outcome and the major
cause of mortality in cancer patients, including prostate cancer (PCa). There are no credible …

Summary Castrate-Resistant Prostate-Cancer (CRPC) is one of the most common
malignancies occurring in men. Unfortunately, even if several recently approved agents …

Nuclear receptor (NR)-mediated transcriptional activity is a dynamic process that is
regulated by the binding of ligands that induce distinct conformational changes in the NR …

Background Although conventional adenocarcinoma accounts for the majority of prostatic
carcinomas, it is important to recognize rare variants, like basal cell carcinoma (BCC), which …

Recent technological advancements in gene expression analysis have led to the discovery
of a promising new group of prostate cancer (PCa) biomarkers that have the potential to …